The evolution of gene therapy manufacturing

Cell & Gene Therapy Insights 2023; 9(11), 1475

DOI: 10.18609/cgti.2023.194

Published: 21 December 2023
Rachel Legmann

Watch the video or view the poster for insights into:

  • KrosFlo TFDF-based perfusion culture intensification and scalability: how to increase the number of cells producing virus with enhanced specific viral vector productivity
  • The importance of continuous perfusion to intensified AAV and lentivirus production
  • How to achieve high recovery and consistency between control benchtop and large-scale runs
  • Streamlining AAV, pDNA, and mRNA titer determination using variable pathlength analytic technology
  • The evolving landscape of innovative process intensification technologies for vector manufacturing

Rachel Legmann has more than 20 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors, and proteins for gene therapy and biologics. Rachel joined Repligen in 2021 as a subject matter expert, leading the vector business unit and setting the strategy around this fast-growing area.